Polyethylene glycol (PEG) is attached to many peptides, proteins, liposomes, and nanoparticles to reduce their immunogenicity and improve their pharmacokinetic and therapeutic properties.
Introduction
Attachment of polyethylene glycol (PEG), a hydrophilic, nontoxic, and nonantigenic biocompatible polymer, to peptides and proteins can enhance drug stability (1) and bioavailability (2) as well as reduce immunogenicity (3) . PEGylation of polymeric nanoparticles, liposomes, and micelles can also greatly extend their circulation time in the body, enhance tumor accumulation, and decrease systemic toxicity, which in turn can improve therapeutic efficacy (4, 5) . PEGylation has, therefore, been widely used to improve the properties of diagnostic and therapeutic agents.
Nanocarriers can accumulate in tumors via the enhanced permeability and retention effect due to leakage of nano-sized materials through the tumor vasculature and defects of lymphatic clearance within tumors (6) . In addition to the enhanced serum half-life afforded by PEGylation, covalent attachment of targeting ligands or antibodies to PEGylated nanocarriers can further increase their uptake into tumor cells via receptor-mediated endocytosis. For example, PEGylated liposomes covalently linked to anti-HER2 Fab fragments (fragment antigen binding) are more effective than nontargeted liposomes for the treatment of mouse breast cancer xenografts (7), due to increased uptake of the immunoliposomes in tumor cells (8) . However, the processes of covalently conjugating antibodies can damage their binding activity, alter the physiologic and pharmacodynamic properties of nanocarriers, and generate new antigenic epitopes (9) . Furthermore, covalent attachment of antibodies to nanocarriers can hinder the release of therapeutic payloads inside cells (10) , thereby decreasing treatment efficacy. Covalent attachment of antibodies to nanoparticles can also greatly complicate the manufacturing process.
Bispecific antibodies (BsAb) are antibody derivatives that possess two distinct antigen-binding specificities. BsAbs have been developed to simultaneously block two antigens expressed on cancer cells (11) , establish crosslinks to activate effector cells at cancer cells (12) , and deliver payloads containing drugs, toxins, and imaging reagents to tumors (13) . Here, we describe new bispecific (hybrid) antibodies with dual specificities for PEGylated compounds or nanocarriers and tumor antigens (Fig. 1A) . We show that a humanized hybrid antibody in an intact IgG 1 format was able to tether PEGylated compounds to HER2 þ cells and increase the in vitro cytotoxicity of liposomal doxorubicin to HER2 þ cancer cells. 2 were purchased from Sigma-Aldrich. PEGASYS (PEG-IFN-alfa-2a) was from Roche and Neulasta (PEGylated granulocyte-colony stimulating factor, G-CSF) was a gift from Amgen. Qtracker655 (Qdot655), a nanocrystal semiconductor coated with multiple linear CH 3 O-PEG 2K molecules, was purchased from Invitrogen. Alexa Fluor 647-N-hydroxysuccinimide ester (NHS ester) was purchased from Molecular Probes. Doxisome (PEGylated liposomal doxorubicin) was from Taiwan Liposome Company, Ltd. Recombinant HER2 extracellular domain (ECD) was a gift from Dr. An-Suei Yang (Genomics Research Center, Academia Sinica, Taiwan). Anti-HER2 antibody (Herceptin) used for detecting surface HER2 expression on various cell lines via FACS analysis was from Roche. Distearoyl phosphatidylcholine (DSPC) and distearoyl phosphatidylethanolamine-PEG 2K (DSPE-PEG 2K ) were purchased from Avanti Polar Lipids. (14, 15) . Viral transformed human embryonal kidney 293 FT cells were kindly provided by Dr. Ming-Zong Lai (Institute of Molecular Biology, Academia Sinica, Taiwan) in 2012. All cell lines were Mycoplasma free and cultured according to the suppliers' recommendations. Hybridoma cells, 293 FT cells, and HCC-36 cells were cultured in DMEM (Sigma-Aldrich) supplemented with 6 g/L HEPES, 3.7 g/L NaHCO 3 , 10% heat-inactivated FBS (HyClone), penicillin (100 U/mL), and streptomycin (100 mg/ mL). SK-BR-3, MCF-7, BT-474, Jurkat, Raji, Ramos, HT29, and SW-480 cells were cultured in RPMI-1640 (Life Technologies) supplemented with 6 g/L HEPES, 2 g/L NaHCO 3 , 10% heatinactivated FBS (HyClone), penicillin (100 U/mL), and streptomycin (100 mg/mL). All cells were cultured at 37 C in a humidified atmosphere of 5% CO 2 in air. No authentication besides confirming surface expression levels of CD19 or HER2 was performed by the authors.
Materials and Methods

Reagents
Hybrid antibodies
A schematic of hybrid antibody expression constructs is shown in Fig. 1B . The V H -C H 1 and V L -C k fragments of mouse anti-PEG backbone antibody 6.3 were amplified from the cDNA isolated from 6.3 hybridoma cells and humanized as described (16) . To facilitate heterodimer formation of the hybrid antibodies, mutations were introduced by site-directed mutagenesis in the human IgG 1 C H 3 domain (S354C and T366W) to create a knob structure and mutations in a separate IgG 1 C H 3 domain (S349C, T366S, L368A, and Y407V) to create a hole structure (17, 18) . The humanized 6.3 V H -C H 1 domain, assembled with the human IgG 1 Fc domain with knob mutations via assembly PCR (19) , was cloned into the pLNCX-hbG-e-B7 vector (20) to acquire the human Ig k leader sequence (Ig k LS) at the N terminus of the humanized 6.3 (h6.3)-knob heavy-chain expression sequence, whereas an HA tag downstream of the Ig k LS was removed. A furin-2A (F2A; ref. 21)-based bicistronic sequence, and the humanized 6.3 V L -C k domain with a Ig k LS sequence inserted at the N terminus, were cloned into the pLNCX-Ig k LS-h6.3-knob heavy-chain expression vector to form a Ig k LS-h6.3-knob heavychain F2A-Ig k LS-h6.3 light-chain expression cassette. The entire h6.3-knob antibody expression cassette was subsequently cloned into the lentivirus expression vector pLKOAS3w-hyg (RNAi core; Academia Sinica).
The human anti-HER2 antibody sequence was cloned from the pBub-YCMC plasmid kindly provided by Prof. Louis M. Weiner of Fox Chase Cancer Center (Philadelphia, PA; ref. 22) . A human anti-CD19 (BU12) antibody sequence (23) was cloned via assembly PCR. The C H 1 and C k domains of the HER2 and the CD19 antibodies were individually exchanged, to promote paring of the correct light and heavy chains (24) . The V H -C k domains of the anti-HER2 or anti-CD19 antibodies, assembled with the human IgG 1 Fc domain with hole structure mutations (S349C, T366S, L368A, and Y407V) via assembly PCR, were cloned into pLNCX-hbG-e-B7 vector (20) to acquire the human Ig k LS and HA tag at the N terminus of the anti-HER2-hole and anti-CD19-hole heavy-chain expression sequence. A F2A bicistronic sequence and the V L -C H 1 domains of the anti-HER2 or anti-CD19 antibodies with an Ig k LS sequence inserted at the N terminus, were cloned into the pLNCX-Ig k LS-HA-anti-HER2-hole or pLNCX-Ig k LS-HA-anti-CD19-hole heavy-chain expression vector. The entire anti-HER2-hole or anti-CD19-hole antibody expression cassette was cloned into the lentivirus expression vector pLKOAS3w-pur (RNAi core; Academia Sinica).
Production of recombinant proteins
Recombinant lentivirus particles were packaged by cotransfection of pLKOAS3w-hyg aPEG-knob, and either pLKOAS3w-pur aCD19-hole or pLKOAS3w-pur aHER2-hole, together with pCMVDR8.91 packaging plasmid and pMD.G VSV-G envelope plasmid (RNAi core, Academia Sinica). 293 FT cells were seeded at 15% of confluence in a 6-well plate in DMEM medium containing 10% FBS 24 hours before viral infection. On the next day, the cells were infected with lentivirus particles expressing aPEG-knob and aCD19-hole, or aPEG-knob and aHER2-hole in the presence of 5 mg/mL polybrene (Sigma-Aldrich). Twenty-four hours later, the cells were selected with hygromycin (0.5 mg/mL) and puromycin (3 mg/mL) to generate stable cell lines expressing aPEG:aCD19 or aPEG:aHER2 hybrid antibodies.
Purification of hybrid antibodies
A total of 5 Â 10 7 of selected 293FT cells stably expressing hybrid antibodies in 15 mL culture medium (DMEM with 10% low bovine IgG medium, serum was preabsorbed with protein A Sepharose 4 Fast Flow chromatography; GE Healthcare) were cultured in a CELLine adhere 1,000 two-compartment bioreactor (Integra Biosciences AG). Antibody-containing culture medium was harvested every week. The pooled supernatant was centrifuged at 910 Â g for 15 minutes at 4 C to remove cells and subsequently centrifuged at 21600 Â g for 30 minutes at 4 C to remove cell debris. The affinity purification process is summarized in Supplementary Fig. S1 . Briefly, the clarified supernatant was passed through a G25 column (GE Healthcare) in PBS, and the hybrid antibodies were affinity purified by protein A Sepharose 4 Fast Flow chromatography (GE Healthcare) and eluted in 0.1 mol/L glycine buffer (pH 3.5) to remove mismatched or excess light chains. The eluted products were further purified by cyanogen bromide (CNBr)-CH 3 O-PEG 1K -NH 2 affinity chromatography (35 mg of CH 3 O-PEG 1K -NH 2 conjugated per gram of CNBr activated Sepharose 4B) using PBS-T (0.05% Tween-20) as the elution buffer to remove aHER2-hole or aCD19-hole homodimers. Subsequently, the eluted hybrid antibodies were purified by affinity chromatography using Pierce anti-HA agarose (Thermo Scientific) and 3 mol/L SCN as the elution buffer to remove aPEGknob homodimers. Purified hybrid antibody fractions were pooled and dialyzed against PBS three times after each affinity purification step, concentrated using Amicon Ultra (30 kD cutoff; Millipore) and sterile filtered.
Mass spectrometry
The molecular weight of intact hybrid antibodies was determined on a Voyager DE-STR MALDI-TOF mass spectrometer (AB Sciex). 1.5 mg antibody in 0.5 mL water was spotted onto a polished steel target and mixed directly onto the plate with 0.5 mL of 45 mmol/L sinapinic acid in 30% acetonitrile/0.3% trifluoroacetic acid. The samples were allowed to air dry, and then loaded into the mass spectrometer. The instrument was operated in the linear positive ion mode with accelerating voltage of 25 kV and delayed extraction of 1,700 ns to acquire the molecular weight of intact proteins. To improve the signal-to-noise ratio, 600 shots were averaged for each mass spectrum. An external mass spectrum calibration was performed using the IgG Calibration Standard Kit (AB Sciex).
Anti-PEG antibody ELISA
Maxisorp 96-well microplates (Nalge-Nunc International) were coated with 10 mg/mL CH 3 O-PEG 2K -NH 2 , NH 2 -PEG 3K -NH 2 , OH-PEG 5K -NH 2 , or CH 3 O-PEG 20K -NH 2 in 50 mL per well 0.1 mol/L NaHCO 3 /Na 2 CO 3 (adjusted to pH 8.0 with HCl) buffer for 3 hours at 37 C and then blocked with 200 mL per well dilution buffer (5% skim milk in PBS) at 4 C overnight. Graded concentrations of anti-PEG antibodies E11, 3.3 or 6.3 in 50 mL 2% skim milk in PBS were added to the plates at room temperature (RT) for 1 hour. The plates were washed with PBS containing 0.1% 3-[(3-cholamidopropyl) dimethylammonio]-1-propanesulfonate (CHAPS; Sigma-Aldrich) three times. Horseradish peroxidase (HRP)-conjugated goat anti-human IgG fragment crystallizable region (Fc) antibody (Sigma-Aldrich) in 50 mL dilution buffer were used for detecting bound anti-PEG antibodies on the microplates. After incubating for 1 hour at RT, the plates were washed as described above. The bound peroxidase activity was measured by adding 100 mL per well ABTS solution [0.4 mg/mL, 2,2 0 -azinobis(3-ethylbenzthiazoline-6-sulfonic acid), 0.003% H 2 O 2 , and 100 mmol/L phosphate-citrate, pH 4.0) at RT. The absorbance (405 nm) of wells was measured in a microplate reader (Molecular Device).
Cell-based ELISA
To measure hybrid antibody binding to cancer cells, 96-well microplates were coated with 2 mg per well poly-L-lysine (40 mg/mL) in PBS for 30 minutes at 37 C, washed twice with PBS and then coated with 2 Â 10 5 SK-BR-3 (HER2 þ ) or MCF-7 (HER2 À ) cells per well. The cells were centrifuged at 910 Â g for 5 minutes and then fixed with 4% para-formaldehyde for 20 minutes at RT. The plates were washed with PBS four times and blocked with 200 mL per well 2% skimmed milk in PBS at 4 C overnight. The plates were then incubated with graded concentrations of hybrid antibodies at RT for 1 hour, then washed with PBS-T (0.05% Tween-20) five times and incubated with HRPconjugated goat anti-human IgG Fc (Sigma-Aldrich) for 1 hour at RT. The plates were washed with PBS-T three times and PBS twice. A 100 mL per well ABTS solution, 0.003% H 2 O 2 , 100 mmol/L phosphate citrate, pH 4.0) was added for 40 minutes at RT, and the absorbance of the wells at 405 nm was measured on a microplate reader.
Flow cytometer analysis
To test the dual binding activity of purified hybrid antibodies to cancer cells and PEGylated nanoparticles, 2. PEGylated protein preparation CH 3 O-PEG 2K -succinimidyl propionic acid (SPA; Shearwater) dissolved in DMSO at 2 mg/mL was mixed with BSA (10 mg/mL) or b-glucuronidase (10 mg/mL) at a molar ratio of PEG to protein of 10 for 2 hours at RT to produce PEGylated BSA or PEGylated b-glucuronidase. One-tenth volume of 1 mol/L glycine solution was added to stop the reaction. PEGylated BSA was purified via gel filtration using Sephacryl S-300 HR (GE Healthcare) and PEGylated b-glucuronidase was purified via ion exchange using DEAE Sephadex A-50 (Pharmacia).
Liposome preparation
For generation of PEG-liposomes, DSPC and DSPE-PEG 2K and cholesterol were dissolved in chloroform at a 65:5:30 molar ratio, respectively. Naked liposomes were prepared using DSPC:cholesterol at a molar ratio of 70:30. A dried lipid film was formed at 65 C by rotary evaporation (B€ uchi, Rotavapor RII) and rehydrated in Tris buffered saline (50 mmol/L TrisHCl, 150 mmol/L NaCl, pH 7.4) at 65 C to a final lipid concentration of 10 mg/mL. The liposomal suspension was submitted to 5 freeze/thaw cycles using liquid nitrogen followed by extrusion 11 times at 70 C through 400, 200, and 80 nm polycarbonate membranes each using a mini-extruder (Avanti Polar Lipids, Inc.). Final lipid concentrations were measure by Bartlett's assay (25) .
Cell-based sandwich ELISA
Cells were coated in 96-well microplates as previously described and fixed. After adding graded concentrations of hybrid antibodies in PBS for 1 hour, the plates were washed and then incubated with fixed concentrations of naked liposomes (1.4 mg/mL lipid), PEG-liposomes (1.4 mg/mL lipid), E.coli C in an atmosphere of air containing 5% CO 2 . After washing with RPMI growth medium supplemented with 10% heat-inactivated FBS, the cells were stained with 10 mg/mL aPEG:aHER2 or aPEG:a CD19 hybrid antibodies in 500 mL RPMI growth medium supplemented with 10% heat-inactivated FBS for 30 minutes. After washing the cells, 10 nmol/L Qdot655 in 500 mL RPMI growth medium was added to the cells and further incubated for 5 hours at 37 C before the fluorescence signals were detected on a Zeiss LSM780 laser-scanning microscope (Carl Zeiss AG). day, 2 or 10 mg/mL aPEG:aHER2 or 10 mg/mL control aPEG:a CD19 hybrid antibodies and graded concentrations of doxisome were added in triplicate to the wells for 3 hours at 37 C. After removing the medium and adding fresh medium, the cells were incubated for 48 hours and then pulsed with The percentage of 3 H-thymidine incorporation ¼ 100 Â (average sample 3 H-thymidine cpm/average untreated control 3 Hthymidine cpm). IC 50 values were calculated by fitting the data to a log (inhibitor) versus responses (variable slopes model) with Prism 5 software (GraphPad Software).
Statistical analysis
Statistical significance of differences between mean values was estimated with Excel (Microsoft) using the independent Student t test for unequal variances. P values <0.05 were considered statistically significant.
Results
Anti-PEG monoclonal antibody 6.3 binds PEG with high affinity
We have generated several hybridoma cells (E11, 3.3 and 6.3) that secrete IgG monoclonal antibodies with specificity for the repeating ethylene oxide subunits in the PEG backbone (15, 27) . The anti-PEG antibodies were compared for binding to amino-PEG coated in 96-well ELISA plates (Supplementary Methods and Supplementary Fig. S2 ). Amino-PEG was used because the terminal amine group allows stable attachment of the PEG molecules to the microplates. 6.3 bound to wells coated with PEG 5K with an apparent affinity that was 14-fold greater than 3.3, and 34-fold greater than E11 anti-PEG antibodies (Supplementary  Table S1 ). Likewise, 6.3 displayed superior binding to short methylated PEG (CH 3 O-PEG 2K ) or long methylated PEG (CH 3 O-PEG 20K ) molecules as compared with 3.3 and E11 antibodies ( Supplementary Fig. S2B and S2C) . We therefore chose to use 6.3 to construct hybrid antibodies due to the higher affinity of 6.3 as compared with our previous best IgG anti-PEG antibody 3.3 (15) .
Expression and purification of hybrid antibodies
We developed two hybrid antibodies: aPEG:aHER2, which targets the well-known tumor antigen HER2/neu that is overexpressed in 20% to 30% of human breast and other adenocarcinomas and aPEG:aCD19, which targets CD19, a surface coreceptor overexpressed in the majority of B cell tumors. Recombinant DNA technology was used to create hybrid antibodies derived from the cDNA coding regions of the V H and V L domain of either humanized anti-HER2 or anti-CD19 antibodies, and humanized 6.3 anti-PEG monoclonal antibody using the "knobsinto-holes" strategy (17) and the immunoglobulin domain crossover approach (24) for heterodimer formation and correct antibody heavy-and light-chain assembly. The construction map of aPEG:aCD19 and aPEG:aHER2 hybrid antibodies is shown in Fig. 1B . The heavy-chain and light-chain domains of both half antibodies were linked with a F2A bicistronic sequence and cloned into lentivirus expression vectors. The constructs were used to produce lentivirus particles, which were subsequently used for generation of stable 293 FT producer cells. The secreted hybrid antibodies (aPEG:aCD19 and aPEG:aHER2) in the culture medium were sequentially affinity purified on protein A resin, CNBr-PEG 1K beads and anti-HA Sepharose ( Supplementary  Fig. S1 ). SDSPAGE analysis showed that purified hybrid antibodies were composed of two heavy chains ($55 kDa) and two light chains ($25 kDa) under reducing conditions (Fig. 1C) . The molecular weights of aPEG:aHER2 and aPEG:aCD19 hybrid antibodies were 153.8 and 152.4 kDa, respectively, as determined by MALDI-TOF.
Functional characterization of hybrid antibodies
The purified hybrid antibodies were first analyzed for binding to different PEG molecules by direct ELISA. aPEG:aHER2 and aPEG:aCD19 showed similar binding to ELISA microplates coated with methoxy PEG (Fig. 2A) , diamine PEG (Fig. 2B) , and PEG (Fig. 2C) , whereas no binding was observed in wells coated with human fibronectin (Fig. 2D) or BSA (Fig. 2E) . These results show that the hybrid antibodies retained PEG-binding activity.
FACS analysis using an anti-HER2 (Herceptin) antibody was used to determine HER2 levels on the surface of live HT29 and SW-480 human colon colorectal adenocarcinoma cells, HCC-36 human hepatocellular carcinoma cells, as well as on SK-BR-3, BT-474, and MCF-7 human breast cancer cells (Supplementary Methods). SK-BR-3 cells expressed the highest levels of HER2, followed by BT-474 cells whereas essentially background levels of HER2 were detected on MCF-7, HT-29, SW-480, and HCC-36 cells (Supplementary Fig. S3 ). Binding of the hybrid antibodies to selected cancer cells was then examined by cell-based ELISA. aPEG:aHER2 bound to HER2
þ SK-BR-3 cells but not to HER2 À MCF-7 cells (Fig. 3A) . As expected, aPEG:aCD19 did not bind to either SK-BR-3 or MCF-7 cells (Fig. 3A) . These results indicate that aPEG:aHER2 could selectively bind to cells that express HER2 on their surface. The affinity of aPEG:aHER2 to HER2 ECD was determined by plasmon resonance measurement in a Biacore T200 (GE Healthcare; Supplementary Methods). Different concentrations of aPEG:aHER2 (8 nmol/L to 128 nmol/L) were flowed through the cell on a CM5 chip immobilized with HER2 ECD proteins and plasmon resonance was measured. Burkitt's lymphoma cells (Fig. 3B, solid lines) . On the other hand, aPEG:aCD19 promoted the binding of Qdot655 to CD19 þ Ramos and Raji cells but not to the CD19 À cells (Fig. 3B, dashed lines). We conclude that the hybrid antibodies can selectively target a PEGylated nanoparticle to cells that express the corresponding antigen on their surface. The ability of aPEG:aHER2 to mediate delivery of various PEGylated compounds to cells that expresses HER2 was investigated by cell-based sandwich ELISA. aPEG:aHER2 could tether PEGylated proteins and liposomes to HER2 þ SK-BR-3 cells (Fig. 3C) . Binding required PEG because naked liposomes or proteins were not retained at HER2 þ cells (Fig. 3C) . aPEG:aHER2 also mediated binding of commercially available PEGylated nanoparticles (Qdot655) and medicines (PEGASYS and Neulasta) to SK-BR-3 cells (Fig. 3D) . By contrast, aPEG:aCD19 did not promote the binding of PEGylated compounds to HER2 þ SK-BR3 cells (Fig. 3E) and aPEG:aHER2 did not mediate binding of PEGylated compounds to HER2 À MCF-7 cells (Fig. 3F ). Taken
together, these results demonstrate that aPEG:aHER2 could mediate specific delivery of diverse PEGylated entities to cancer cells that express HER2 on their surface.
aPEG:aHER2 can induce endocytosis of PEGylated nanoparticles into HER2 þ cancer cells
We investigated whether aPEG:aHER2 could promote the internalization of Qdot655 PEGylated nanoparticles into tumor cells. Confocal microscopy demonstrated that aPEG:aHER2 ) . B, schematic of hybrid antibody expression constructs. aPEG-knob codes for a human Igk signal peptide, the humanized VH domain of anti-PEG antibody 6.3, a human IgG1 heavy chain with knob mutations (S354C, T366W), followed by a F2A bicistronic sequence, the humanized VL domain of 6.3 and a human Ck domain. aCD19-hole and aHER2-hole code for a human Igk signal peptide, a HA tag, the humanized VH domain of an anti-CD19 or anti-HER2 antibody, a human Ck domain, a human IgG1 heavy-chain Fc domain with hole mutations (S349C, T366S, L368A, and Y407V), followed by a F2A bicistronic sequence, a human Igk signal peptide, the humanized VL domain of the anti-CD19 or anti-HER2 antibody and a human IgG1 CH1 domain. CH, heavy-chain constant domain; VH, heavy chain variable domain; VL, light chain variable domain; Ck, k light chain constant domain; LS, leader sequence; HA, human influenza hemagglutinin epitope tag. C, reducing SDSPAGE showing the purified hybrid antibodies and half antibodies separately expressed by different 293 FT cell clones; H, heavy chain; L, light chain.
could specifically deliver Qdot655 to SK-BR-3 cells, accompanied with accumulation of Qdot655 inside cells after 5 hours of incubation at 37 C (Fig. 4A, top) . By contrast, the uptake of Qdot655 was not observed in SK-BR-3 cells incubated with control aPEG:aCD19 hybrid antibody and Qdot655 (Fig. 4A,   bottom ). Binding and uptake of Qdot655 was also not observed in HER2
À MCF-7 cells treated with aPEG:aHER2 (Fig. 4B) . We conclude that aPEG:aHER2 can mediate selective binding and internalization of PEGylated nanoparticles into HER2 þ cancer cells. This assay measures cell proliferation and gives similar results as the tetrazolium MTT assay (28, 29) . aPEG:aHER2 but not aPEG:aCD19 significantly enhanced the cytotoxicity of doxisome to SK-BR-3 ( Fig. 5A ) and BT-474 (Fig. 5B ) HER2 þ cancer cells as compared with treatment with doxisome alone. The similar cytotoxicity observed with doxisome and both 10 and 2 mg/mL aPEG:aHER2 suggests that sufficient hybrid antibody was present to saturate the HER2 receptors on SK-BR-3 cells (Fig. 5A) . The IC 50 values of doxisome in combination with aPEG:aHER2 were over two orders of magnitude lower than with doxisome alone (Table 1 ). Neither aPEG:aHER2 or aPEG:aCD19 altered the sensitivity of HER2 À MCF-7 cells to doxisome (Fig. 5C) , showing that the hybrid antibodies displayed specificity for cells that expressed target ligand. The hybrid antibodies alone did not induce cytotoxicity in SK-BR-3 and BT-474 cells (Fig. 5D ).
Discussion
We developed and investigated hybrid antibodies consisting of PEG-binding and tumor antigen-binding half antibodies. The hybrid antibodies are capable of delivering diverse PEGylated compounds and nanoparticles to cancer cells that express surface antigens recognized by the tumor antigen-binding half antibody. We found that a aPEG:aHER2 hybrid antibody facilitated the uptake of nanoparticles into HER2 þ cancer cells and greatly enhanced the cytotoxicity of doxisome to HER2 þ cancer cells.
We anticipate that anti-PEG hybrid antibodies may serve as a versatile approach for targeted delivery of PEGylated compounds (therapeutic proteins, liposomal drugs, gene delivery carriers, or imaging agents) to tumors and other cellular locations, and may further enhance therapeutic and diagnostic efficacy due to the enhanced cellular uptake of PEGylated compounds. We previously described anti-PEG IgG antibodies (3.3 and E11) with well-characterized binding to PEG (14, 15, 30) . However, we were unable to achieve good tumor targeting using E11 or 3.3 anti-PEG antibodies, supposedly due to insufficient binding affinity to PEG (unpublished results). We therefore developed a new anti-PEG monoclonal antibody, 6.3, which displayed about one order of magnitude higher apparent affinity to PEG molecules as compared with our previous high-affinity anti-PEG IgG monoclonal antibody 3.3 ( Supplementary Fig. S2 and Supplementary  Table S1 ). These results suggest that high affinity is required for the anti-PEG arm of the hybrid antibodies for good delivery of PEGylated compounds to cellular targets.
Although PEGylation can extend the half-lives and stability of nanoparticles, the steric hindrance provided by PEG molecules can interfere with desired interactions with target cells. For example, PEG molecules on nanocarriers designed for delivery of DNA or siRNA were found to hamper cellular uptake (31), which is known as the "PEG dilemma" (32) . DNA or siRNA must be transported across the cell plasma membrane to enter cells, but the interactions between the gene carriers and cell surface are blocked by the aqueous phase surrounding the PEG moieties. Therefore, although PEGylation can extend the stability and half-lives of nanoparticles, a trade-off exists as the interactions between the PEGylated compounds and their targets might also be hampered by PEGylation.
Active targeting has been one approach to enhance cellular uptake of PEGylated compounds. Target ligands recognizing receptors specifically overexpressed on cancer cells have been covalently linked to PEGylated nanoparticles, which in turn promote selective binding and uptake of the nanoparticles by target cells. Proteins, peptides containing specific motifs such as arginine-glycine-aspartic acid (RGD; ref. 33) , folate (34), antibodies and antibody fragments (immunoliposomes), nucleic acids (35) , and transferrin (36) have been conjugated to PEGylated nanoparticles to facilitate active targeting.
Anti-PEG hybrid antibodies may possess some advantages compared with other targeting technologies. Chemical conjugation is complicated by potential damage to the targeting ligand and cargo (10, 37) as well as by generation of immunogenic epitopes. Interactions between cellular receptors and conjugated ligands can also be hampered by the steric hindrance provided by PEG moieties (38) . By contrast, well-characterized hybrid antibodies specific to PEG molecules and cellular receptors may exert consistent binding of both target cells and PEGylated compounds under physiologic conditions, omitting complexities resulted from conjugation reactions. Moreover, payloads noncovalently bound by antibodies may be a more efficient alternative for cargo release, as targeting ligands may require degradation or complicated cleavage processes to release the active cargos (10). Importantly, separation of antibody development and nanoparticles or drug development may allow for simpler manufacturing processes. Other BsAbs have been developed to deliver nanocargos to cellular targets. For example, BsAbs recognizing both a chemical hapten and a tumor antigen were shown to successfully target hapten-conjugated vehicles to specific cells (13, 39) . However, chemical conjugation of haptens to the payloads is required. PEGylation of hapten-conjugated nanoparticles can also hinder binding of anti-hapten BsAbs (40) . We overcame this limitation by creating BsAbs that directly bind to PEG molecules already present on many nanaomedicines.
In contrast with our previously described anti-methoxy-PEG BsAb fragments (26) , here, we investigated intact IgG 1 hybrid antibodies that bind to the ethylene oxide backbone of PEG. One potential advantage of human IgG 1 hybrid antibodies is the opportunity for both targeted delivery of therapeutic agents and induction of anticancer immune responses. The Fc domain of human IgG 1 when bound to the surface of cancer cells can activate complement and trigger antibody-dependent cellular cytotoxicity (ADCC) by immune effector cells (natural killer cells and monocytes), which contribute to effective antibody therapies (41) . It will be of interest to determine whether there are any synergistic effects between ADCC and hybrid antibody delivery of nanomedicines. Immunostimulatory PEGylated cytokines such as IL2, IFNa, IFNg, and IL12 (42) may also represent rational targets for selective tumor delivery by anti-PEG hybrid antibodies.
In conclusion, our study suggests that anti-PEG hybrid antibodies offer a simple and versatile method to selectively deliver PEGylated compounds the target cells. Examples of clinically used PEGylated proteins include PEG-asparaginase (43) (47) . PEGylated nanomedicines include such examples as polyplex, a nanoparticle inhalation gene delivery system for gene therapy (48) , stealth radiolabeled PEG 2K -liposomes and 
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